Clinical trial efficacy evaluation of omega-3 on seizures control of children with refractory epilepsy and attention-deficit/hyperactivity disorder

Razieh Fallah, Shiva Eiliaei, Farzad Ferdosian



Objective: This study was done to answer the question that whether or not previous antiepileptic drugs with combination of omega-3 and risperidone is more efficient than previous antiepileptic drugs with risperidone alone in decreasing of seizures monthly frequency of children with refractory epilepsy and attention-deficit/hyperactivity disorder (ADHD).

Methods: In a randomized clinical trial, sixty four 7-11 year old children with refractory epilepsy and ADHD who were referred to Pediatric Neurology Clinic of Shahid Sadoughi Hospital, Yazd, Iran from June 2015, were distributed into two groups, randomly. In group I, one capsule of omega-3 daily and 0.5 mg of risperidone was divided into two doses with previous antiepileptic drugs and in group II, 0.5 mg of risperidone was divided into two doses with previous antiepileptic drugs were given. The drugs use was continued for three months and the children were followed up monthly for three consecutive months. Primary outcomes included seizure monthly frequency and good response (more than 50% of reduction in seizures monthly frequency). Secondary outcome was clinical side effects.

Results: 23 girls and 33 boys with mean age of 9.24+0.15(29 children in omega-3 group and 27 children in control group) were evaluated. Omega-3 therapy was effective in decreasing of seizures monthly frequency (10.41±3.92 times vs. 17.01±4.98, P = 0.03). Good response was seen in three children (11.1%) in control (95% confidence interval: 8%-22.8%) and in 9 children (20%) in Omega-3 (95% CI: 47.83%-14.17%) group, which showed that omega-3 was more effective in seizure controlling. (P=0.001) Frequency of side effects was not different in the two groups (14.8 % in control vs. 20.7% in omega-3 groups, P=0.5).

Conclusion: Omega-3 might be used as an effective and safe drug in seizures control of children with refractory epilepsy and ADHD.


Epilepsy, Refractory Epilepsy, Omeg-3, ADHD

Full Text:




Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55(4):475-82.

Berg AT. Identification of pharmacoresistant epilepsy. Neurol Clin 2009; 27(4):1003-13.

Sinha S, Siddiqui KA. Definition of intractable epilepsy. Neurosciences (Riyadh) 2011; 16(1):3-9.

French JA. Refractory epilepsy: one size does not fit all. Epilepsy Curr 2006; 6(6):177-80.

Urion DK. Attention deficit/hyperactivity disorders. Kliegman RM, Stanton BF, St Geme JW, Schor NF. Nelson Textbook of Pediatrics. Philadelphia, Elsevier 2016; 20th edition, Pp: 200-204.

Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 2015; 56(3):345-65.

Bertelsen EN, Larsen JT, Petersen L, Christensen J, Dalsgaard S. Childhood Epilepsy, Febrile Seizures, and Subsequent Risk of ADHD. Epilepsia 2016; 57(7):1069-77.

Socanski D, Aurlien D, Herigstad A, Thomsen PH, Larsen TK. Epilepsy in a large cohort of children diagnosed with attention deficit/hyperactivity disorders (ADHD). Seizure 2013; 22(8):651-5.

Tsai FJ, Liu ST, Lee CM, Lee WT, Fan PC, Lin WS, Chiu YN, Gau SS.ADHD-related symptoms, emotional/behavioral problems, and physical conditions in Taiwanese children with epilepsy. J Formos Med Assoc 2013 ;112(7):396-405.

Cohen R, Senecky Y, Shuper A, Inbar D, Chodick G, Shalev V, Raz R. Prevalence of epilepsy and attention-deficit hyperactivity (ADHD) disorder: a population-based study. J Child Neurol 2013;28(1):120-3.

Tejada S, Martorell M, Capó X, Tur JA, Pons A, Sureda A. Omega-3 fatty acids in the management of epilepsy. Curr Top Med Chem 2016; 16(17):1897-905.

LaChance L, McKenzie K, Taylor VH, Vigod SN. Omega-6 to Omega-3 Fatty Acid Ratio in Patients with ADHD: A Meta-Analysis. J Can Acad Child Adolesc Psychiatry 2016; 25(2): 87-96.

Bos DJ, Oranje B, Veerhoek ES, Van Diepen RM, Weusten JM, Demmelmair H, et al. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder. Neuropsychopharmacology 2015; 40(10):2298-306.

Reda DM, Abd-El-Fatah NK, Omar Tel-S, Darwish OA. Fish oil intake and seizure control in children with medically resistant epilepsy. N Am J Med Sci. 2015; 7(7):317-21.

DeGiorgio CM, Miller PR, Harper R, Gornbein J, Schrader L, Soss J, Meymandi S. Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study. J Neurol Neurosurg Psychiatry 2015; 86(1):65-70.

Yuen AW, Flugel D, Poepel A, Bell GS, Peacock JL, Sander JW. Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy. Epilepsy Behav 2012; 23(3):370-2.

Yuen AW, Sander JW, Fluegel D, Patsalos PN, Bell GS, Johnson T, Koepp MJ. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav 2005; 7(2):253-8.

Schlanger S,Shinitzky M,Yam D. Diet enrichedwith omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients.Epilepsia 2002;43(1):103-4.

Yoon JR, Lee EJ, Kim HD, Lee JH, Kang HC. Polyunsaturated fatty acid-enriched diet therapy for a child with epilepsy. Brain Dev 2014; 36(2):163-6.

Bromfield E, Dworetzky B, Hurwitz S, Eluri Z, Lane L, Replansky S, Mostofsky D. A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav 2008; 12(1):187-90.

Taha AY, Burnham WM, Auvin S. Polyunsaturated fatty acids and epilepsy. Epilepsia. 2010; 51(8):1348-58.

Scorza FA, Cysneiros RM, Arida RM, Terra-Bustamante VC, de Albuquerque M, Cavalheiro EA. The other side of the coin: Beneficiary effect of omega-3 fatty acids in sudden unexpected death in epilepsy. Epilepsy Behav 2008; 13(2):279-83.



  • There are currently no refbacks.

Copyright (c) 2018 Iranian Journal of Child Neurology